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Abstract. Objective: To assess the role of nitric oxide in 
the most relevant local and systemic manifestations in mice 
injected with the venom of the snake Bothrops asper. Mice 
were pretreated with nitric oxide synthase inhibitors, and 
the modifi cations of the pathological effects induced by the 
venom were tested.
Results: Inhibition of NO synthesis did not affect acute 
local myonecrosis and hemorrhage in muscle tissue upon 
intramuscular injection of venom. Local footpad edema was 
reduced in mice pretreated with the NO synthase inhibitor 
L-NAME, and a reduction in the extent of infl ammatory 
infi ltrate in muscle tissue was observed after envenomation 
in mice pretreated with L-NAME and aminoguanidine. The 
most pronounced effect of NOS inhibition by L-NAME was 
an increment in the lethal activity of the venom, when in-
jected by the intraperitoneal route.
Conclusion: Nitric oxide does not seem to play a signifi cant 
role in the local acute pathological alterations (hemorrhage 
and myonecrosis) induced by B. asper venom in mice, al-
though it contributes to edema and infl ammatory infi ltrate. 
Nitric oxide exerts a protective role in the systemic patho-
physiological manifestations leading to lethality.
Key words: NO synthase – NO – L-NAME – Bothrops as-
per venom – myonecrosis – hemorrhage – lethality
Introduction
Envenomations by pit vipers (family Viperidae, subfamily 
Crotalinae) constitute a public health hazard in many re-
gions of the world [1, 2]. In Central America, most snakebite 
envenomations are infl icted by Bothrops asper [3], a large 
and widely distributed species in tropical rainforests and in 
altered areas devoted to agriculture and cattle raising [4]. 
Venoms of Bothrops sp snakes in general, and of B. asper in 
particular, induce envenomations of complex pathophysiolo-
gy associated with prominent tissue alterations (hemorrhage, 
edema, necrosis, blistering) at the site of venom injection 
and, in moderate and severe cases, with systemic pertur-
bations (hemodynamic alterations, defi brination and other 
manifestations of coagulopathy and renal effects) [2, 3].
The pathogenesis of local and systemic effects induced by B. 
asper venom has been partially investigated. Various locally-
acting toxins, mostly metalloproteinases and phospholipases 
A2, are responsible for the acute local pathological effects 
[5–7]. In addition, a variety of venom components, such as 
metalloproteinases, serine proteinases and proteins of the C-
type lectin family, induce defi brination, systemic bleeding 
and thrombocytopenia, therefore promoting profuse bleed-
ing and coagulopathy [8–12]. Furthermore, experimental 
and clinical evidence indicates that B. asper envenomations 
also concur with a conspicuous infl ammatory response, both 
local and systemic, which might contribute to the pathophys-
iology of envenomation [13–18]. However, despite their well 
demonstrated occurrence, the precise role of infl ammatory 
mediators as contributors to local and systemic tissue dam-
age in these envenomations remains obscure.
Nitric oxide (NO) is a short-living mediator implicated in 
an amazing variety of tissue and cellular processes [19]. 
Increments in NO synthesis have been demonstrated in 
experimental animals injected with B. asper venom [15, 
20]. Owing to the role that NO plays in various models of 
cardiovascular shock, and as precursor of tissue-damaging 
peroxynitrites [19], the possibility has been raised that incre-
ments in NO production in Bothrops sp envenomations may 
contribute to the complex pathophysiology characteristic of 
this pathology [15, 20]. Inhibition of NO synthesis drastical-
ly reduced the extent of myonecrosis induced by crotoxin, a 
myotoxic and neurotoxic phospholipase A2 complex present 
in the venom of the rattlesnake Crotalus durissus terrifi cus 
[21]. Therefore, the elucidation of the role of NO in the 
pathogenesis of tissue damage infl icted by snake venoms is a 
relevant task. The present investigation assessed the involve-
ment of NO in the local and systemic effects induced by B. 
asper venom in a murine experimental model.Correspondence to: J. M. Gutiérrez
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mice received an i. m. injection, in the right gastrocnemius muscle, of 
50 µg venom, dissolved in 100 µL SS. Controls were injected with SS 
alone. One hr after envenomation, mice were killed by CO2 overdose, 
and the injected gastrocnemius muscles were dissected out and cut into 
small pieces to quantify the amount of hemoglobin [25]. Tissue was 
placed in 2.0 mL of Drabkin solution and left at 4 ºC for 24 h. After cen-
trifugation at 600 × g, the supernatant was collected and its absorbance 
at 540 nm was recorded as a quantitative estimation of the amount of 
hemoglobin present in the tissue as a consequence of hemorrhage. 
Inhibition of myotoxic activity. Mice pretreated as described were inject-
ed i. m., in the right gastrocnemius muscle, with 50 µg of B. asper venom, 
dissolved in 100 µL of saline solution. Control mice received SS alone. 
Three hr after envenomation, mice were anesthetized with CO2 and bled 
from the tail, blood being collected into heparinized capillary tubes. The 
plasma creatine kinase (CK) activity was determined using the Sigma 
kit No. 47-UV. In some experiments, mice were killed by an overdose 
of CO2 24 h after envenomation, and both envenomated and contralat-
eral gastrocnemius muscles were dissected out and homogenized, as 
previously described [26]. After centrifugation at 5000 × g for 5 min, the 
supernatants were diluted 1:35 with saline solution, and CK activity of 
the supernatants was determined as described. Residual CK activity in 
envenomated muscle was expressed as percentage, taking as 100 % the 
CK activity of non-envenomated, contralateral gastrocnemius. 
Inhibition of edema-forming activity. Mice pretreated as described re-
ceived a s. c. injection of 2.5 µg B. asper venom, dissolved in 50 µL SS. 
Other groups of pretreated mice were then injected s. c. with 50 µL of SS 
without venom. This dose was selected because it induces evident edema 
without hemorrhage [14]. A group that received venom was injected si-
multaneously with sodium nitroprusside. The thickness of injected foot-
pads was measured at various time intervals with a low pressure spring 
caliper (H.C. Kröplin, Germany) [13], and edema was expressed as the 
percentage increment in thickness of envenomated footpad as compared 
with the footpad injected with SS only.
Effects on infl ammatory cell infi ltrate. Mice pretreated as described were 
injected i. m. in the right gastrocnemius muscle with either 50 µg of B. as-
per venom, dissolved in 100 µL of SS or with 100 µL of SS alone. Then, at 
24, 48 and 72 h, animals were killed and the injected gastrocnemius mus-
cles were dissected out and chopped with a blade into very small pieces 
before addition of 2 mL of SS containing trypsin. The rest of the proce-
dure was performed as previously described [26]; briefl y, the suspension 
was incubated for 15 min at 4 °C and then for 20 min at 37 °C, with mild 
agitation every 5 min. Then, it was fi ltered through gauze, and the gauze 
was washed with an additional 1 ml of SS. Filtered suspensions were cen-
trifuged and the pellet was resuspended in 200 µL of SS. Total leucocyte 
counts in these suspensions were performed in a Neubauer chamber. 
Inhibition of systemic effects
Inhibition of venom-induced lethality. Groups of 5 mice each were pre-
treated as described above. Then mice were injected i. p. with various 
amounts of venom, dissolved in 200 µL of SS. Deaths were recorded 
during 48 h and LD50 was estimated by using the probits method. In 
another type of experiment, mice receiving the same pretreatments were 
challenged with 2 LD50s of venom by the i. p. route. Animals were ob-
served and the time of death recorded. Controls received saline solution 
instead of venom.
Inhibition of defi brinating effect. Groups of 5 mice each were pretreated 
as described above. Then, various amounts of venom (1.5 µg, 3.0 µg and 
6.0 µg, dissolved in 200 µL of SS) were administered intravenously 
(i. v.) in the tail. Control mice were injected with 200 µL of SS alone. 
One hr later, and under CO2 anesthesia, animals were bled by cardiac 
puncture, blood was placed in clean, dry glass tubes, and clotting times 
were recorded. 
Changes in blood leucocyte and platelet counts. Groups of 6 mice each 
were pretreated as described above. Then, they were injected i. p. with 
Materials and methods
Venom and drugs
B. asper venom was obtained from more than 40 adult specimens col-
lected in the Pacifi c region of Costa Rica and kept at the serpentarium of 
Instituto Clodomiro Picado. Upon collection, venom was immediately 
lyophilized and stored at –20 °C. Immediately before its use, venom was 
dissolved in apyrogenic and sterile saline solution (150 mM NaCl) (SS) 
and fi ltered through 0.22 µm membranes. The following drugs were 
used: Ng-nitro-L-arginine methyl ester (L-NAME), Ng-nitro-D-arginine 
methyl ester (D-NAME), aminoguanidine, nitroprusside and L-arginine, 
all from Sigma-Aldrich (St. Louis, MO, USA). Drugs were dissolved in 
SS immediately before their use.
Protocols used for administration of drugs
Swiss mice (18–20 g), obtained from the Animal Colony of Instituto Bu-
tantan (Sao Paulo, Brazil), were used. Throughout the study, mice were 
maintained on a 12 h: 12 h light: dark cycle and received food and water 
ad libitum. L-NAME and D-NAME were injected intraperitoneally 
(i. p.), at a dose of 50 mg/kg, 24 h and 30 min before venom injection 
[20]. Aminoguanidine, an inhibitor of iNOS [22], was administered 
i. p. 24 h and 30 min before venom injection, at doses of 50 mg/kg and 
100 mg/kg, respectively [20]. Sodium nitroprusside was used in experi-
ments dealing with edema and myonecrosis, and was injected subcutane-
ously (s.c.) (for edema) and intramuscularly (i. m.) (for myonecrosis), at 
a dose of 5 mg/kg. L-arginine was administered i. p. 24 h and 1 h before 
venom injection at a dose of 300 mg/kg. Some animals were pretreated 
with SS alone. After these drug pretreatments, mice were injected with 
B. asper venom or SS to assess the extent of local and systemic altera-
tions, as described below. Drug pretreatments and venom administration 
protocols were approved by the Committee for the Care and Use of 
Animals (CICUA) of the University of Costa Rica.
Quantifi cation of NO in envenomated muscle
Groups of 5 mice received an i. m. injection, in the right gastrocnemius 
muscle, of 50 µg of B. asper venom, dissolved in 100 µL of SS. Control 
mice received 100 µL of SS alone. At various time intervals (1 h, 3 h, 6 h, 
24 h, 48 h) animals were killed and the injected gastrocnemius muscles 
were dissected and homogenized on ice with a 50 mM Tris, 0.1 mM 
ethylene diamine tetracetic acid (EDTA), 0.1 mM ethylene glycol 
bis (2-aminoethyl ether)-N, N, N′ N′-tetracetic acid (EGTA), 12 mM 
2-mercaptoethanol, 1 mM phenylmethylsulphonyl fl uoride (PMSF), 
pH 7.4 (Sigma-Aldrich), using a Polytron PT MR 3000 homogenizer 
(Brinkmann, Westbury, NY). Then, samples were centrifuged 7 min at 
13,000 g. Nitrate was extracted according Wu and Yen [23]. Nitrate was 
then converted to NO by the addition of a reducing agent (0.8 % VCl3 in 
1N HCl). The sample was then applied to a Sievers Nitric Oxide analys-
er 280 NOA (Sievers, Boulder, CO, USA). Nitrate concentrations were 
calculated by comparison with standard solutions of NaNO3 (Sigma). In 
another experiment, the increments in muscle NO were studied in groups 
of mice pretreated with either saline solution, L-NAME or aminoguani-
dine, as described before. Then, 1 h after venom injection, mice were 
killed and muscle NO concentration was determined as described. 
Inhibition of venom-induced local effects
Inhibition of hemorrhagic activity. Mice (18–20 g) were pretreated as de-
scribed, and then injected intradermally (i. d.), in the ventral abdominal 
region, with 20 µg of B. asper venom, dissolved in 100 µL of SS. This 
dose corresponds approximately to 10 minimum hemorrhagic doses, 
i. e. ten times the amount of venom that induces a hemorrhagic halo of 
10 mm diameter [24]. Two hr after envenomation, mice were killed by an 
overdose of CO2, and the diameters of the hemorrhagic halos in the inner 
side of the skin were measured. In another type of experiment, pretreated 
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ed in a signifi cantly larger hemorrhagic lesion in mice when 
compared with animals pretreated with SS or D-NAME (Fig. 
2A). However, when hemorrhagic activity was assessed in 
muscle tissue, mice pretreated with either L-NAME or 
aminoguanidine did not differ in the extent of hemorrhage, 
assessed by the amount of hemoglobin present in the tissue, 
when compared with control mice pretreated with SS or D-
NAME (Fig. 2B).
Myotoxic activity. Mice injected i. m. with SS alone showed 
plasma CK activity of 200 ± 25 U/L 3 h after injection. 
Plasma CK activity increased drastically in mice pretreated 
with SS and then receiving an i. m. injection of B. asper 
venom, refl ecting a prominent myonecrotic process (Fig. 
3A), as has been previously described [28]. No signifi cant 
variations in the plasma CK activity was observed in mice 
pretreated with either L-NAME, D-NAME or aminoguani-
dine, despite a trend of increment in myonecrosis in mice 
receiving L-NAME (Fig. 3A). Moreover, when myonecrosis 
was quantitated by assessing the reduction in muscle CK ac-
tivity at 24 h, there were no differences between the various 
experimental groups (Fig. 3B). Pretreatment of animals with 
the NO-enhancing compounds L-arginine and nitroprusside 
did not affect the extent of myonecrosis (results not shown).
Edema-forming activity. Mice injected s. c. in the footpad 
with B. asper venom developed an edema of rapid onset 
which peaked 1 h after injection (Fig. 4). When mice were 
pretreated with D-NAME, no signifi cant changes were 
observed in the curve of edema, whereas pre-treatment 
with L-NAME signifi cantly reduced the extent of this effect 
50 µg venom, dissolved in 200 µL SS; this corresponds to a venom dose 
slightly lower than LD50 [27]. Control mice were injected with 200 µL 
of SS alone. One and three hr after injection, mice were bled by cardiac 
puncture, under CO2 anesthesia. Total and differential leucocyte counts, 
as well as platelet counts, were performed in an automated hematological 
analyzer (Micros 60, ABX Hematologie, France). 
Statistical analyses. The Student’s t test was used to determine the 
signifi cance of the differences between two pairs of means. When 
more than two means were compared, Analysis of Variance was used, 
followed by Tukey-Kramer test to compare pairs of means. A P value of 
0.05 was selected to establish signifi cance.
Results
Increment of NO in envenomated muscle
A signifi cant increment in the NO content of gastrocnemius 
muscle was observed in mice injected with SS and with 
50 µg B. asper venom, when compared with non-injected 
muscle. Increments were signifi cantly higher in envenom-
ated mice than in SS-injected mice at 1, 3, 6 and 24 h (Fig. 
1A). When mice were pretreated with either L-NAME or 
aminoguanidine, the venom-induced increments in NO were 
abrogated (Fig. 1B). 
Effects of inhibition of NO synthesis in local tissue damage
Hemorrhagic activity. When using the mouse intradermal 
test, pre-treatment with L-NAME or aminoguanidine result-
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Fig. 1. (A) NO concentration in mouse gastrocnemius muscle after i. m. injection of either saline solution (white bars) or venom (fi lled bars). As con-
trol, NO from muscle of mice that did not receive saline solution or venom is included (shaded bar). Saline (100 µL) or venom (50 µg/100 µL) were 
injected i. m. in the right gastrocnemius muscle. At various time intervals, mice were sacrifi ced and injected muscles were dissected out and homog-
enized. Nitrate was extracted from tissues and converted to NO in order to determine its concentration in an analyzer, as described in Materials and 
methods. (B) Effect of pre-treatment with various drugs on NO synthesis in gastrocnemius muscle. Animals were pretreated with either saline solution 
(SS), L-NAME (L) or aminoguanidine (AG); then, they were injected i. m. with either saline solution (SS) or venom (V). One hour after venom or SS 
injection, mice were sacrifi ced and muscle NO quantifi ed as described. Results are presented as mean ± SEM (n = 5). In (A) * P < 0.05 when comparing 
saline solution group versus venom group. In (B) * P < 0.05 when compared with mice pretreated with SS and then injected with venom.
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Fig. 2. (A) Effects of pre-treatment with NOS inhibitors in skin and mus-
cle hemorrhage induced by B. asper venom. Mice were pretreated with 
either saline solution, L-NAME, D-NAME or aminoguanidine (AMG), 
as described in Materials and methods. Then, venom (20 µg/100 µL) was 
injected intradermally in the abdominal region. Two hr later, mice were 
sacrifi ced, their skin dissected and the diameter of the hemorrhagic le-
sion in the inner part of the skin measured. (B) Other groups of mice, 
pretreated as described, were injected i. m. in the right gastrocnemius 
muscle, with 50 µg venom/100 µL. One hr after envenomation, mice 
were sacrifi ced and injected muscles were dissected out and homog-
enized. After centrifugation, the haemoglobin concentration of the su-
pernatant was determined. Results are presented as mean ± SEM (n = 5). 
* P < 0.05, ** P < 0.01 when compared with the group pretreated with 
saline solution and then injected with venom. 
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Fig. 3. Effects of pre-treatment with NOS inhibitors in myotoxicity 
induced by B. asper venom. Mice were pretreated with either saline so-
lution, L-NAME, D-NAME or aminoguanidine (AMG), as described in 
Materials and methods. Then, venom (50 µg/100 µL) was injected i. m. in 
the right gastrocnemius muscle. At various time intervals after enveno-
mation, plasma CK activity was determined (A). Then, 24 h after en-
venomation, mice were sacrifi ced and both right and left gastrocnemius 
muscles were dissected out and homogenized, followed by centrifuga-
tion. CK activity of the supernatant was determined and residual CK in 
envenomated muscle was expressed as percentage, taking as 100 % the 
CK activity of the left, non-envenomated muscle (B). Results are pre-
sented as mean ± SEM (n = 5). No signifi cant differences were observed 
between any of the experimental groups (P > 0.05).
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(Fig. 4). In order to assess if this effect was due to iNOS, 
mice were pretreated with aminoguanidine; however, there 
was not a reduction in the extent of edema when compared 
with mice pretreated with SS in these circumstances (results 
not shown).
Leucocyte infi ltrate in muscle. A prominent infl ammatory 
infi ltrate was observed in gastrocnemius muscle injected 
with B. asper venom, as previously described [26, 29]. Such 
infi ltrate increased with time, reaching highest numbers by 
72 h (Fig. 5A). Pretreatment with L-NAME caused a signifi -
cant reduction in the infi ltrate at 72 h, but not at 24 or 48 h 
(Fig. 5A). Pretreatment with aminoguanidine also promoted 
a reduction in the infi ltrate at 72 h. In contrast, no differences 
were observed at any time interval between mice pretreated 
with SS and those pretreated with D-NAME (Fig. 5B).
Effects of inhibition of NO synthesis in systemic alterations
Lethality. LD50 in mice pretreated with SS and then injected 
i. p. with venom was 63.5 µg in 16–18 g mice (95 % confi -
dence limits: 53.7–73.2 µg), a value similar to one previously 
reported for this venom [27]. Pretreatment with L-NAME 
signifi cantly reduced the value of LD50, refl ecting an incre-
ment in the toxicity of the venom in these conditions (LD50: 
43.3 µg; 95 % confi dence limits: 36.1–47.0 µg). In contrast, 
no signifi cant variation in the value of LD50 was observed 
in mice pretreated with D-NAME (LD50: 64.4 µg; 95 % 
confi dence limits: 54.8–104.4 µg), aminoguanidine (LD50: 
57.7 µg; 95 % confi dence limits: 51.4–67.1 µg) or L-arginine 
(LD50: 63.4 µg; 95 % confi dence limits: 48.7–84.9 µg). When 
a venom dose corresponding to 2 LD50s was injected i. p. in 
mice pretreated with either SS or L-NAME, there was a sig-
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nifi cant difference in the time of death, since mice pretreated 
with L-NAME died at earlier time intervals than those pre-
treated with SS (Fig. 6).
Defi brination. Mice injected i. v. with SS only had a whole 
blood clotting time of 121 ± 56 sec, whereas mice receiving 
B. asper venom developed a characteristic dose-dependent 
defi brination syndrome, as previously described [30]. Doses 
of 1.5 and 3.0 µg did not prolong the clotting time when 
compared with mice receiving SS alone (112 ± 34 sec and 
88 ± 14 sec, respectively; P > 0.05). Mice pretreated with 
L-NAME and then receiving SS presented clotting time of 
137 ± 40 sec (P > 0.05 when compared with control mice 
injected with SS only). In contrast, mice receiving 6.0 µg 
venom were defi brinated, i. e. had unclottable blood, in both 
L-NAME and SS-pretreated groups. Thus, NOS inhibition 
did not modify venom-induced defi brination.
Leucocyte and platelet counts. Mice pretreated with SS and 
then injected with venom by the i. p. route did not show sig-
nifi cant variations in the total leucocyte and platelet counts 
when compared with control mice injected with SS instead 
of venom (Table 1). However, there was a signifi cant change 
in the percentage of polymorphonuclear leucocytes (at 1 h) 
and monocytes (at 1 and 3 h). Envenomated mice had less 
polymorphonuclear leucocytes and more monocytes than 
control mice (Table 1). The same changes were observed in 
envenomated mice that had been pretreated with either L-
NAME or D-NAME (Table 1). 
Discussion
An increment in NO levels was demonstrated in skeletal 
muscle rapidly after i. m. injection of B. asper venom. Such 
a rapid elevation may depend on the activity of constitutive-
ly-expressed NOS, known to be present in skeletal muscle 
[31]. However, the ability of pre-treatment with aminogua-
nidine to abrogate such NO increment strongly suggests 
that it depends on inducible forms of NOS associated with 
resident macrophages or with infl ammatory cells reaching 
affected tissue after the insult [26, 29]. An increment in the 
expression of iNOS, together with an increase in protein 
nitrosylation, was previously demonstrated in peritoneal 
macrophages 48 h after ip injection of this venom [20]. 
Animals injected with SS alone had muscle NO levels higher 
than non-injected control mice, probably indicating that the 
mechanical damage induced by SS injection induces a small 
extent of NO synthesis.
NO has been implicated in acute muscle damage in vari-
ous experimental models in vivo and in cell culture. Muscle 
cells cocultured with both neutrophils and macrophages 
developed a NO-dependent cytotoxic process [32], and inhi-
bition of NOS by L-NAME decreased the extent of muscle 
cell damage in an experimental model of modifi ed muscle 
use [33], as well as in models of muscle crush injury [34]. 
Furthermore, knockout mice for iNOS develop less muscle 
injury in a model of ischemia-reperfusion [35]. Regarding 
snake venoms, pre-treatment with L-NAME drastically ab-
rogated the extent of myonecrosis induced by crotoxin [21], 
a highly potent neurotoxic and myotoxic phospholipase 
A2 responsible of the paralysis and systemic myotoxic-
ity characteristic of envenomations by the South American 
rattlesnake Crotalus durissus terrifi cus [36, 37]. On these 
grounds, it was of interest to assess if NO plays a role in B. 
asper venom-induced local myonecrosis. Our observations 
clearly argue against this hypothesis, since no signifi cant 
differences in the release of CK from damaged muscle were 
observed between envenomated mice pretreated with SS, 
L-NAME, D-NAME and aminoguanidine. Previous stud-
ies had shown that other participants of the infl ammatory 
reaction, i. e. neutrophils, matrix metalloproteinases and the 
cytokines TNF-α, IL-1β and IL-6, are not directly involved 
in acute myonecrosis in a similar experimental model of B. 
asper envenomation [14, 18, 26]. Hence, local myonecrosis 
induced by this venom very likely depends on the direct 
toxic effects of myotoxic phospholipases A2 [5, 28] and 
hemorrhagic metalloproteinases [38, 39]. The former infl ict 
muscle damage by directly affecting the integrity of skeletal 
muscle cell plasma membrane [7, 28], whereas myonecrosis 
induced by hemorrhagic proteinases is likely to be secondary 
to the ischemia resultant in the tissue from the deleterious ef-
fects on blood supply [39]. It is necessary to carry out a more 
comprehensive assessment on the role of NO in myotoxicity 
induced by a variety of myotoxic proteins present in other 
snake and arthropod venoms.
Inhibition of NO synthesis infl uenced the extent of skin 
hemorrhage induced by B. asper venom, since pre-treatment 
with L-NAME and aminoguanidine promoted an increment 
in the diameter of the local skin hemorrhagic lesion. How-
ever, when hemorrhage was assessed by quantifying the 
amount of hemoglobin in muscle tissue, no differences were 
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Fig. 6. Effect of pre-treatment with the NOS inhibitor L-NAME in the 
time course of lethality in mice injected with B. asper venom. Groups of 
5 mice were pretreated with either saline solution (discontinuous line) 
or L-NAME (continuous line). Then, they were injected with 2 LD50 of 
venom, dissolved in 200 µL, by the intraperitoneal route. The time of 
death was recorded and survival was expressed as percentage of surviv-
ing mice at a given time point.
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observed between the various experimental groups. This dis-
crepancy may be related to the marked heterogeneity of the 
action of NO in the microvasculature of various organs [40]. 
It is suggested that the effect in skin may be secondary to the 
alterations resultant from NO synthase inhibition in hemo-
dynamic parameters. NOS inhibition promotes an increase 
in blood pressure which, in turn, may contribute to capil-
lary wall rupture after degradation of basement membrane 
components by venom hemorrhagic metalloproteinases. 
Accordingly, it has been proposed that biophysical forces 
operating in the microvasculature in vivo are likely to partici-
pate in the mechanism of venom metalloproteinase-induced 
hemorrhage [41]. Differences in the effect of NO on the 
microvasculature of skin and skeletal muscle may explain 
the differences observed in the two experimental systems. 
Nevertheless, even in the case of skin, the differences in the 
extent of hemorrhage between the different groups were not 
impressive. It can be therefore concluded that NO does not 
seem to play a prominent role in the pathogenesis of B. asper 
venom-induced local hemorrhage. Similar observations were 
performed by Laing et al. [42] in the case of the P-III hemor-
rhagic metalloproteinase jararhagin, from the venom of B. 
jararaca, using knock-out mice for iNOS. 
A signifi cant reduction of venom-induced foot pad 
edema occurred in mice pretreated with L-NAME, thus sug-
gesting that NO participates in this phenomenon. Moreover, 
the fact that L-NAME, but not aminoguanidine, reduced 
venom-induced edema, strongly suggests that constitutive 
eNOS, but not iNOS, plays a key role in this phenomenon. 
Edema induced by Bothrops sp venoms is multifactorial, 
since a number of infl ammatory mediators are involved [14, 
43]. NO participates in the edematogenic effect induced by 
carrageenin in rats [44]. In this case, it was suggested that 
such effect was due to a decrease in local blood fl ow, second-
ary to NO synthase inhibition, and not to an effect in vascular 
permeability [44]. Pain is another effect induced by B. asper 
venom, and previous results evidenced a role for neuronal 
NOS-dependent spinal NO synthesis in hyperalgesia and al-
lodynia caused by intraplantar injections of myotoxic phos-
pholipases A2 present in this venom [45]. In addition, pre-
treatment with L-NAME reduced the extent of infl ammatory 
infi ltrate in muscle tissue 72 h after envenomation, but not at 
24 and 48 h. Also, a similar inhibition was observed at 72 h 
when mice were pretreated with aminoguanidine, strongly 
suggesting the involvement of iNOS in the development 
of infl ammatory infi ltrate in muscle injected with B. asper 
venom. A reduction in infl ammatory infi ltrate, associated 
with reduced L-selectin expression, was described as a con-
sequence of L-NAME treatment in a model of B. jararaca 
venom-induced infl ammation in rats [46]. Hence, despite 
confl icting fi ndings on the role of NO in infl ammatory phe-
nomena (see for example [47] and [48]), which may depend 
on the use of different NOS inhibition protocols and differ-
ences in the microvasculature of various tissues, our fi nd-
ings and those of others suggest that NO promotes various 
aspects of infl ammation in models involving Bothrops sp 
venom injection. The lack of effect of NOS inhibition in the 
infl ammatory infi ltrate at 24 and 48 h suggests that infl am-
matory mediators other than NO play a predominant role in 
leucocyte recruitment at these earlier time intervals.
The most notorious consequence of NO synthase inhibi-
tion in our experimental model was a signifi cant increment 
Table 1. Changes in leucocyte and platelet counts in peripheral blood in mice pretreated with saline solution (SS), L-NAME or D-NAME and then 
injected i. p. with B. asper venoma
1 h after venom injection
Parameter Control (SS) SS + venom L-NAME + venom D-NAME + venom
Total leucocytes (per µL) 3160 ± 251 3960 ± 739 3750 ± 804 3910 ± 439
Polymorphonuclear (%) 26 ± 1.6  13 ± 2.4* 8 ± 1* 13 ± 2.0*
Lymphocytes (%) 61 ± 3.2 62 ± 2.9 67 ± 3.6 58 ± 3.0
Monocytes (%) 13 ± 1.8 25 ± 1.1* 25 ± 2.7* 29 ± 1.6*
Platelets (per µL) 745,160 ± 58,000 696,000 ± 111,000 545,710 ± 85,160 599,028 ± 87,750
3 h after venom injection
Parameter Control (SS) SS + venom L-NAME + venom D-NAME + venom
Total leucocytes (per µL) 3160 ± 251 4660 ± 486 3950 ± 769 5130 ± 791
Polymorphonuclear (%) 26 ± 1.6 19 ± 2.2 18 ± 2.8 22 ± 2.2
Lymphocytes (%) 61 ± 3.2 58 ± 2.4 61 ± 2.6 57 ± 2.6
Monocytes (%) 13 ± 1.8 23 ± 2.2* 21 ± 1.1* 21 ± 2.5*
Platelets (per µL) 745,160 ± 58,000 581,400 ± 60,410 543,500 ± 116,500 545,500 ± 46,300
a
 Control mice received 200 µL of SS alone, by the i. p. route. The other groups of mice were pretreated by the same route with either SS, L-NAME or 
D-NAME; then, they were injected i. p. with 50 µg B. asper venom, dissolved in 200 µL SS. Blood samples were collected 1 h and 3 h after envenoma-
tion and cell counts were determined in an automatic analyzer. Data of controls injected with only SS correspond to samples collected 1 h after injec-
tion. Results are presented as mean ± SEM (n = 6).
* P < 0.05 when compared with values in control mice injected with SS alone. 
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in the lethal effect, and a shortening in the time of death, 
when venom was administered i. p. Such effect is not due to 
alterations in venom-induced coagulopathy nor in variations 
in the numbers of circulating leucocytes or platelets, which 
are conspicuous manifestations in B. asper envenomations 
[3]. It is likely that this effect depends on alterations in he-
modynamic and tissue perfusion parameters. Observations 
with various inhibitors strongly suggest that a constitutive 
form of NOS, probably eNOS, is responsible for this effect, 
since pre-treatment with L-NAME, but not with aminogua-
nidine, increased lethality. NO generated by eNOS has been 
shown to play a critical role in vascular function, and thera-
peutic interventions aimed at increasing eNOS activity have 
been protective in various models of cerebral ischemia [49]. 
After its synthesis in vascular endothelial cells, NO exerts 
cytoprotective effect and contributes to vascular homeostasis 
[49, 50]. Hence, since systemic envenomation by crotaline 
snake venoms is associated with prominent hemodynamic 
disturbances [2, 51], inhibition of eNOS by L-NAME may 
play a deleterious role by jeopardizing the constitutively lo-
cal vascular production of NO by eNOS. The role of NO in 
ischemia is complex and multifactorial, since NO generated 
by iNOS present in infl ammatory cells exerts deleterious 
roles contributing to late-phase damage [52]. Nevertheless, 
our data suggest that the overall effect of NO inhibition in 
this model of B. asper venom-induced lethality is deleterious 
instead of benefi cial. The mechanisms operating behind such 
protective role of NO require further investigation. 
In conclusion, NO does not seem to play a critical role 
in the acute local pathological alterations (hemorrhage and 
myonecrosis) induced by B. asper venom, with the exception 
of a mild protective role on hemorrhagic activity in the skin. 
In contrast, NO contributes to local edema and to late phases 
of infl ammatory infi ltrate. Inhibition of NO synthesis does 
not affect venom-induced coagulopathy. However, inhibition 
of NOS increases the lethal effect of B. asper venom, when 
tested by the i. p. route, thus suggesting that NO has a protec-
tive role in this model of envenomation, probably associated 
with its participation in vascular homeostasis.
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